BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wesch D, Kabelitz D, Oberg HH. Tumor resistance mechanisms and their consequences on γδ T cell activation. Immunol Rev 2020;298:84-98. [PMID: 33048357 DOI: 10.1111/imr.12925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kabelitz D. Gamma Delta T Cells (γδ T Cells) in Health and Disease: In Memory of Professor Wendy Havran. Cells 2020;9:E2564. [PMID: 33266147 DOI: 10.3390/cells9122564] [Reference Citation Analysis]
2 Zhou L, Feng B, Wang H, Wang D, Li Y. A bispecific nanomodulator to potentiate photothermal cancer immunotherapy. Nano Today 2022;44:101466. [DOI: 10.1016/j.nantod.2022.101466] [Reference Citation Analysis]
3 You C, Ning L, Zhang Z, Wu H, Qu Q, Wang F, Xiong R, Huang C. Toxic reactive oxygen species enhanced chemodynamic therapy by copper metal-nanocellulose based nanocatalysts. Carbohydrate Polymers 2022;289:119432. [DOI: 10.1016/j.carbpol.2022.119432] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Serrano R, Lettau M, Zarobkiewicz M, Wesch D, Peters C, Kabelitz D. Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells. OncoImmunology 2022;11:2030021. [DOI: 10.1080/2162402x.2022.2030021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yang R, Shen S, Gong C, Wang X, Luo F, Luo F, Lei Y, Wang Z, Xu S, Ni Q, Xue Y, Fu Z, Zeng L, Fang L, Yan Y, Zhang J, Gan L, Yi J, Zhou P. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells. Front Immunol 2021;12:654080. [PMID: 34040604 DOI: 10.3389/fimmu.2021.654080] [Reference Citation Analysis]
6 Yang R, He Q, Zhou H, Gong C, Wang X, Song X, Luo F, Lei Y, Ni Q, Wang Z, Xu S, Xue Y, Zhang M, Wen H, Fang L, Zeng L, Yan Y, Shi J, Zhang J, Yi J, Zhou P. Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell. Front Immunol 2022;13:923969. [DOI: 10.3389/fimmu.2022.923969] [Reference Citation Analysis]
7 Belghali MY, Admou B, Brahimi M, Khouchani M, Ba-M'hamed S. Immune tumoral microenvironment in gliomas: focus on CD3+ T cells, Vδ1+ T cells, and microglia/macrophages. Immunol Res 2022. [PMID: 35006549 DOI: 10.1007/s12026-022-09260-5] [Reference Citation Analysis]
8 Brauneck F, Weimer P, Schulze Zur Wiesch J, Weisel K, Leypoldt L, Vohwinkel G, Fritzsche B, Bokemeyer C, Wellbrock J, Fiedler W. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma. Front Med (Lausanne) 2021;8:763773. [PMID: 34820398 DOI: 10.3389/fmed.2021.763773] [Reference Citation Analysis]
9 Zhang X, Li X, Xie J, Zhu Q, Yuan Y. A Novel Immune-Related Prognostic Signature Predicting Survival in Patients with Pancreatic Adenocarcinoma. J Oncol 2022;2022:8909631. [PMID: 35342420 DOI: 10.1155/2022/8909631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Serrano R, Coch C, Peters C, Hartmann G, Wesch D, Kabelitz D. Monocyte-dependent co-stimulation of cytokine induction in human γδ T cells by TLR8 RNA ligands. Sci Rep 2021;11:15231. [PMID: 34315922 DOI: 10.1038/s41598-021-94428-6] [Reference Citation Analysis]
11 Déchanet-Merville J, Prinz I. From basic research to clinical application of γδ T cells. Immunol Rev 2020;298:5-9. [PMID: 33245813 DOI: 10.1111/imr.12931] [Reference Citation Analysis]
12 Weimer P, Wellbrock J, Sturmheit T, Oliveira-ferrer L, Ding Y, Menzel S, Witt M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Brauneck F. Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer. Cells 2022;11:964. [DOI: 10.3390/cells11060964] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]